These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18055341)

  • 1. Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy.
    Navarro JT; Ribera JM; Oriol A; Xicoy B; Mate JL; Sirera G; Lloveras N; Millá F; Feliu E
    Int J Hematol; 2007 Nov; 86(4):337-42. PubMed ID: 18055341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
    Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
    Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
    Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
    Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
    Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
    Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
    Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
    J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma.
    Navarro JT; Ribera JM; Oriol A; Romeu J; Sirera G; Mate JL; Batlle M; Xicoy B; Grau J; Millá F; Feliu E
    Leuk Lymphoma; 2002 Sep; 43(9):1837-42. PubMed ID: 12685841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
    Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
    Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
    Portlock CS; Qin J; Schaindlin P; Roistacher N; Myers J; Filippa D; Louie D; Zelenetz AD; O'Brien JP; Moskowitz C; Norton L; Yahalom J; Straus DJ; Bertino JR
    Ann Oncol; 2004 Oct; 15(10):1495-503. PubMed ID: 15367410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
    Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
    Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicpathological features and survival of patients with AIDS related non-Hodgkin's lymphoma].
    Sun KY; Gui XE; Deng D; Xiong Y; Deng LP; Gao SC; Zhang YX
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):97-101. PubMed ID: 28279031
    [No Abstract]   [Full Text] [Related]  

  • 12. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
    Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
    Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
    Toffoli G; Corona G; Cattarossi G; Boiocchi M; Di Gennaro G; Tirelli U; Vaccher E
    Ann Oncol; 2004 Dec; 15(12):1805-9. PubMed ID: 15550586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil.
    Tanaka PY; Pracchia LF; Calore EE
    Int J Hematol; 2006 Nov; 84(4):337-42. PubMed ID: 17118760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
    Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
    Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a Report from Iran.
    Payandeh M; Najafi S; Shojaiyan FZ; Sadeghi M
    Asian Pac J Cancer Prev; 2016; 17(3):1513-7. PubMed ID: 27039799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
    Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
    Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.